Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Farmaka Indonesian Journal of Cancer Chemoprevention
Meilia Suherman
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
MOLEKULAR IMPRINTING POLIMER UNTUK PENGUJIAN ATENOLOL DALAM CAIRAN BIOLOGIS : REVIEW JURNAL Meilia Suherman
Farmaka Vol 15, No 3 (2017): Farmaka
Publisher : Fakultas Farmasi, Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (550.289 KB) | DOI: 10.24198/jf.v15i3.12857

Abstract

Atenolol merupakan obat golongan antagonis β adrenaceptor, atau dikenal juga dengan β1-blocker yang digunakan untuk pengobatan kelainan pada jantung, seperti angina pektoris, hipertensi, aritmia, dan infark moikard (serangan jantung), dan lain-lain. Namun, atenolol juga dianggap sebagai doping bagi altet karena memiliki efek yang dapat mengurangi denyut jantung, tremor pada tangan, dan juga mengurangi kecemasan (anti ansietas) selama pertandingan berlangsung. Hingga saat ini telah banyak metode yang digunakan pengujian atenolol diantaranya metode kromatografi, metode potensiometer, metode voltametri dan metode elektroforesis zona kapiler. Metode-metode tersebut memiliki kelemahan dan  keuntungannya masing - masing seperti faktor biaya, waktu analisis, sensitivitas dan selektivitas. Selain itu pula metode preparasi sampel akan sangat mempengaruhi hasil analisis karena keberadaan atenolol yang berada pada matriks biologi sehingga membutuhkan teknik preparasi yang tepat untuk meningkatkan akurasi dari pembacaan alat. Molecularly imprinted polymers (MIPs) adalah cara yang efektif untuk mengekstrak atau pra-konsentrat target analit dari matriks kompleks sebelum analisis. MIP mempunyai  kemampuan yang selektif dalam mengisolasi senyawa spesifik atau analog strukturalnya dari matriks yang kompleks.
In Silico Study of Bioactive Compounds from Syzygium malaccense Targeting HER2 and Progesterone Receptors in Breast Cancer Nawadhir Fauzan; Riska Prasetiawati; Meilia Suherman; Dhania Novitasari; Muchtaridi Muchtaridi
Indonesian Journal of Cancer Chemoprevention Vol 16, No 1 (2025)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev16iss1pp1-14

Abstract

Breast cancer remains one of the most common causes of cancer-related deaths among women, with progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) being key molecular targets in its progression. This study aimed to explore the potential of bioactive compounds from Syzygium malaccense that have exhibited anticancer activities, as targeted inhibitors for PR and HER2, using computational approaches. A total of 155 compounds were initially screened for anticancer potential using the Prediction of Activity Spectra for Substances (PASS), identifying 80 compounds for further analysis. Drug-likeness and pharmacokinetic predictions indicated that several compounds complied with the Rule of Five (RO5) and had favorable absorption and distribution profiles, suggesting their suitability as oral drug candidates. Molecular docking revealed that quercetin exhibited favorable interactions with PR, particularly involving the ARG 766 residue, while myricetin demonstrated strong binding affinity to HER2, surpassing trastuzumab, and interacting with key residues Asp 863, Lys 753, Ala 751, and Leu 796. Molecular dynamics simulations confirmed the stability of the Myricetin-HER2 complex under physiological conditions over 15 ns, supporting its potential as a HER2 inhibitor. These findings highlight myricetin and quercetin as promising natural compounds for breast cancer therapy targeting HER2 and PR, respectively. However, further experimental validation, including in vitro and in vivo studies, is necessary to confirm their therapeutic efficacy and safety. Overall, this study supports Syzygium malaccense as a valuable source of natural bioactive compounds for breast cancer drug discovery.Keywords: in silico screening, Syzygium malaccense, breast cancer, progesterone receptor, HER2.
Co-Authors Dhania Novitasari Muchtaridi Muchtaridi Nawadhir Fauzan Riska Prasetiawati